Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $163.4 million.

  • Catalyst Pharmaceuticals' Income from Continuing Operations rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • Catalyst Pharmaceuticals' Income from Continuing Operations amounted to $163.4 million in FY2024, which was up 174.43% from $59.5 million recorded in FY2023.
  • Catalyst Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $163.4 million during FY2024, with a 5-year trough of $39.5 million in FY2021.
  • For the 3-year period, Catalyst Pharmaceuticals' Income from Continuing Operations averaged around $102.0 million, with its median value being $83.1 million (2022).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Income from Continuing Operations slumped by 47.35% in 2021 and then spiked by 174.43% in 2024.
  • Catalyst Pharmaceuticals' Income from Continuing Operations (Yearly) stood at $75.0 million in 2020, then plummeted by 47.35% to $39.5 million in 2021, then surged by 110.42% to $83.1 million in 2022, then decreased by 28.34% to $59.5 million in 2023, then soared by 174.43% to $163.4 million in 2024.